Search Result

Isoforms Recommended:	JAK2

Results for "

JAK2V617F

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (8) Autophagy (1) Bcr-Abl (1) FLT3 (6) Isotope-Labeled Compounds (1) JAK (14) RET (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (1) Inflammation/Immunology (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15480

NSC 42834 2 Publications Verification JAK2 Inhibitor V; Z3	JAK	Cancer
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of *Jak2, inhibits Jak2-V617F* and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

HY-10409

Fedratinib Maximum Cited Publications 43 Publications Verification TG-101348; SAR 302503	JAK Apoptosis	Cancer
Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-10409A

Fedratinib hydrochloride hydrate Maximum Cited Publications 43 Publications Verification TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate	JAK Apoptosis	Cancer
Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-10410

TG101209 5 Publications Verification	FLT3 JAK RET Autophagy Apoptosis	Cancer
TG101209 is a selective *JAK2* inhibitor with IC₅₀ of 6 nM, less potent to Flt3 and RET with IC₅₀ of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.

HY-13775

XL019 5 Publications Verification	JAK Apoptosis	Cancer
XL019?is a potent, orally active, and selective *JAK2* inhibitor, with IC₅₀s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 .

HY-10409R

Fedratinib (Standard) TG-101348 (Standard); SAR 302503 (Standard)	JAK Apoptosis	Cancer
Fedratinib (Standard) is the analytical standard of Fedratinib. This product is intended for research and analytical applications. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-10409AR

Fedratinib hydrochloride hydrate (Standard) TG-101348 hydrochloride hydrate (Standard); SAR 302503 hydrochloride hydrate (Standard)	JAK Apoptosis	Cancer
Fedratinib (hydrochloride hydrate) (Standard) is the analytical standard of Fedratinib (hydrochloride hydrate). This product is intended for research and analytical applications. Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-16379R

Pacritinib (Standard)	JAK FLT3	Cancer
Pacritinib (Standard) is the analytical standard of Pacritinib. This product is intended for research and analytical applications. Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM).

HY-10409S

Fedratinib-d9 TG-101348-d₉; SAR 302503-d₉	Isotope-Labeled Compounds Apoptosis JAK	Cancer
Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-118084

LS-104 Tyrene CR-4	JAK Bcr-Abl FLT3 Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
LS-104 (Tyrene CR-4) is a non-ATP-competitive kinase inhibitor against *JAK2, Bcr-Abl* and FLT3. LS-104 potently induces apoptosis in JAK2V617F-positive cells and inhibits *JAK2* autophosphorylation and downstream signal transduction. LS-104 also inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells. LS-104 is a hydroxystyryl-acrylonitrile compound, which is promising for research of myeloproliferative disorders and refractory/relapsed hematologic malignancies .

HY-161684

JAK2-IN-10	JAK	Cancer
JAK2-IN-10 (compound 5) is a potent *JAK2 V617F* inhibitor with an IC₅₀ value of ≤10 nM .

HY-16379

Pacritinib 10+ Cited Publications SB1518	JAK FLT3	Cancer
Pacritinib (SB1518) is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and *JAK2 ^V617F* mutant (IC₅₀=19 nM). Pacritinib also inhibits FLT3 (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM).

HY-16379A

Pacritinib hydrochloride SB1518 hydrochloride	JAK FLT3	Cancer
Pacritinib hydrochloride is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and *JAK2 ^V617F* mutant (IC₅₀=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) .

HY-16379B

Pacritinib citrate 10+ Cited Publications SB1518 citrate	JAK FLT3	Cancer
Pacritinib (SB1518) citrate is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and *JAK2 ^V617F* mutant (IC₅₀=19 nM). Pacritinib citrate also inhibits FLT3 (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM). Pacritinib citrate can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) .

Cat. No.	Product Name	Chemical Structure

HY-10409S

Fedratinib-d9
Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

Fedratinib-d9

Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-161684

JAK2-IN-10
JAK2-IN-10 (compound 5) is a potent *JAK2 V617F* inhibitor with an IC₅₀ value of ≤10 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.